Submassive PE: underrecognized and undertreated | Victor Tapson, MD | ||
|
Professor of Medicine Duke University Medical Center Durham, NC |
||
Reversal of right heart dysfunction within 48 hours of treatment | Tod Engelhardt, MD | ||
|
Chair, Cardiovascular & Thoracic Surgery Division East Jefferson General Hospital Metairie, LA |
||
ULTIMA randomized controlled clinical trial | Iris Baumgartner, MD | ||
|
Professor of Internal Medicine University Hospital Bern, Switzerland |
||
Aggressive treatment of submassive pulmonary embolism | Peter Lin, MD | ||
|
Professor of Surgery Baylor College of Medicine Houston, TX |
||
Panel Discussion | |||
CE Marked Indications: The EkoSonic® Endovascular Device is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic® Endovascular Device is intended for the treatmeent of pulmonary embolism patients with a ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressure (mean pulmonary artery pressure ≥ 25 mmHg) or echocardiogram evaluation.
US FDA Cleared Indications: The EkoSonic® Endovascular Device is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic® System is cleared for the infusion of solutions into the pulmonary arteries.
Information presented will include treatment not yet cleared by FDA.